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The CAPRISA 004 preexposure prophylaxis (PrEP) randomized trial demonstrated that women who used a vag-
inal gel containing the antiretroviral drug tenofovir (TFV) had a 39% lower risk of acquiring human immuno-
deficiency virus (HIV). It is not known whether topical TFV alters the antibody response to breakthrough HIV
infection. In this study, antibody maturation was evaluated using 3 serologic assays: the BED capture enzyme
immunoassay (CEIA), the Bio-Plex (Luminex) assay, and the Bio-Rad avidity assay. Tests were performed using
serum samples collected 3, 6, 9, 12, 24, 36, 48, and >48 months after seroconversion from 95 women in the
CAPRISA 004 trial (35 in the TFV gel arm and 60 in the placebo arm). For the BED CEIA and Luminex
assay, linear mixed effects models were used to examine test results by study arm. Cox proportional hazard anal-
ysis was used to examine time to avidity cutoff. Anti-HIV antibody titers did not differ between study arms.
Women assigned to TFV gel demonstrated slower antibody avidity maturation, as determined by the Bio-Rad
(P = .04) and gp120 Bio-Plex (P = .028) assays. Women who were assigned to receive topical TFV but became
infected had slower antibody avidity maturation, with potential implications for diagnosis and antibody-based
incidence assays as access to antiretroviral therapy–based PrEP is increased.
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The use of tenofovir (TFV) or TFV/emtricitabine
(TFV/FTC) for preexposure prophylaxis (PrEP) in
human immunodeficiency virus (HIV)–uninfected in-
dividuals has been found to be effective in reducing
HIV incidence [1–3]. The first study to demonstrate
the effectiveness of TFV-based PrEP was the CAPRISA
004 trial. In that trial, women were randomized to
receive 1% TFV vaginal gel or placebo gel, and women
in the TFV arm were found to be 39% less likely to ac-
quire HIV infection during the study [1]. Other studies
that have evaluated use of TFV gel for PrEP have had
mixed results, in part because of low adherence to
PrEP regimens in some studies [4].
Previous studies have shown that the titer and avidity
of anti-HIV antibody responses are diminished in indi-
viduals who start antiretroviral therapy (ART) during
the acute phase of HIV infection [5]. Because antiretro-
viral drugs inhibit viral replication, the serologic re-
sponse to HIV infection may also be different in
individuals who acquire HIV infection while taking
PrEP, compared with those who acquire HIV infection
in the absence of antiretroviral drug exposure. A previ-
ous study in rhesus macaques demonstrated that TFV/
FTC PrEP suppressed the simian immunodeficiency
virus load and antibody avidity maturation in break-
through infections but that the overall antibody titer
and neutralizing antibody titer were not affected [6].
In this report, we evaluated the anti-HIV antibody
response in women who acquired HIV infection in
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the TFV and placebo arms of the CAPRISA 004 trial [1] and
were subsequently followed in a seroconverter cohort study
conducted at the same study sites (CAPRISA 002) [7]. The sam-
ples were analyzed using a variety serologic assays that were de-
veloped for cross-sectional estimation of the incidence of HIV
infection. These assays measure characteristics of the humoral
immune response to HIV infection that usually evolve during
the course of HIV infection. In particular, they measure the pro-
portion of immunoglobulin G (IgG) that is HIV specific, anti-
body titer, and antibody avidity [8–10].
METHODS
Ethics Statement
All of the samples analyzed in this report were obtained in a
previous study (CAPRISA 002/CAPRISA 004). During the
study, written informed consent was obtained from study par-
ticipants for the use of their samples in future investigations.
The study was reviewed and approved by the University of
KwaZulu Natal Biomedical Research Ethics Committee (refer-
ence E013/04). Only stored samples from individuals who con-
sented to inclusion of their samples in future research were used
in this investigation. No new samples were obtained for this
study. The research described in this report was approved by
the Institutional Review Board of the Johns Hopkins University
School of Medicine. The research was conducted according to
the principles expressed in the Declaration of Helsinki.
Study Population
Plasma samples were obtained from the CAPRISA 004 trial [1]
and CAPRISA 002 Seroconverter Cohort Study [11]. HIV-
uninfected women were enrolled in the CAPRISA 004 trial.
During the CAPRISA 004 trial, women were requested to use
the study product (vaginal gel) in relation to coitus, with inser-
tion of 1 dose of gel within 12 hours before sex and a second
dose of gel as soon as possible within 12 hours after sex and
no more than 2 doses of gel in a 24-hour period (BAT 24).
Gel adherence was assessed each month by self-report and via
counts of returned applicators. Study product was discontinued
if women in either study arm acquired HIV infection; HIV-
infected women were enrolled in the CAPRISA 002 Seroconver-
tor Cohort Study. The date of HIV seroconversion was estimated
as the midpoint between last visit when a woman had negative
results of HIV antibody and HIV RNA tests and the first visit
when she had a positive result of an HIV antibody test [12]; for
women with a positive HIV RNA test result and a negative HIV
antibody test result during a visit, the date of HIV seroconver-
sion was estimated as 13 days after that visit. Samples were
requested from the following study visits: <3, 3–6, 6–9, 9–12,
12–24, 24–36, 36–48, and >48 months after the estimated
date of seroconversion. Women were only included if samples
were available from at least 2 of these visits.
Laboratory Testing
HIV load and CD4+ T-cell counts were measured as previously
described [1]. Three serologic assays were performed in this
study. The first assay was the BED capture enzyme immunoas-
say (CEIA; Calypte Biomedical Corporation, Lake Oswego,
OR), which measures the proportion of IgG that is specific to
an immunodominant region of HIV-1 gp41 [8]. This assay
was performed according to the manufacturer’s instructions,
with the following modification: all samples were run in dupli-
cate, and the average normalized optical density (OD-n) was
used for analysis; samples with an OD-n of <0.8 were character-
ized as assay positive. The second assay, Bio-Rad avidity assay, is
a modified version of the Genetic Systems 1/2+O ELISA (Bio-
Rad, Hercules, California) [10]. This assay measures antibody
avidity; the target antigens are recombinant gp160 and p24 pro-
teins. Samples were diluted 1:10 in duplicate and incubated at 4°
C for 30 minutes (the initial antibody-binding step). Samples
were then incubated for 30 minutes at 37°C (the antibody-
disassociation step), with or without the chaotropic agent dieth-
ylamine (DEA; diluted in deionized water). For each sample, the
avidity index (AI) was calculated as [optical density of the dieth-
ylamine-treated well]/[optical density of the nontreated
well] × 100. Samples with AIs of <80% were characterized as
having positive results. The third assay, the Bio-Plex (Luminex)
assay, was used to measure both anti-HIV IgG titer and anti-
body avidity. This assay was performed as previously described,
with the exception that magnetic COOH beads (Bio-Rad Labo-
ratories, Hercules, California) were used for the antigen-cou-
pling procedure, as opposed to polystyrene beads, which were
used in earlier studies [11].The beads were coupled with recom-
binant HIV-1 gp120, gp160, and 2 forms of gp41 proteins (gp41
intact and gp41 truncated; Immunodiagnostics, Woburn,
Massachusetts, the truncated peptide was produced by the
CDC Core Facility). All plasma samples were tested in dupli-
cate. A normalized mean fluorescent intensity (MFI) was cal-
culated for each sample and was compared to the MFI of a
calibrator; the AI was determined from these 2 values, as previ-
ously described [11].
Statistical Methods
Kaplan–Meier plots, log-rank tests, and Cox proportional
hazard models were used to compare the time to the cutoff
for each assay (duration that samples were assay positive) in
the TFV and placebo study arms, adjusting for viral load and
CD4+ T-cell count, when appropriate. Time points were cen-
sored from the analysis when the subject initiated antiviral
treatment. The rate of increase of antibody titer or avidity, mea-
sured using the Luminex assay, was compared in the 2 study
arms for each of the 4 target antigens; differences in antibody
avidity were examined using linear mixed effects. Frequencies
were compared using the Fisher exact test or the χ2 test, when
appropriate.
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RESULTS
Anti-HIV antibody maturation was evaluated in 553 samples
from 95 women who acquired HIV infection in the CAPRISA
004 trial; 35 were in the TFV arm, and 60 were in the placebo arm
(Table 1).While TFV exposure at the time of HIV infection could
not be assessed, median gel adherence in the 35 seroconverters
assigned to receive TFV gel was 55%, based on an average of 7
returned empty applicators per month. The mean number of
samples tested per woman and the mean age at the time of
HIV acquisition were the same for the 2 study arms. The mean
CD4+ T-cell count at the first HIV-positive visit and the median
log10 HIV load during follow-up (after infection) were similar for
women in the 2 study arms. Seventeen women initiated ART dur-
ing the study, and 3 women died during follow-up (Table 1).
Results obtained using the BED CEIA and Bio-Rad avidity
assay are shown in Figure 1. The failure to obtain an assay-
positive result indicates delayed or absent antibody maturation.
Time trends for the proportion of IgG that is HIV specific after
HIV seroconversion were similar for the 2 study arms. The pro-
portion of women who had an assay-positive result throughout







Samples, no. 197 356 .81
Samples/woman, no.
Mean ± SD 6 ± 1 6 ± 1
Range 3–7 4–7 .43
Age at infection, y
Mean ± SD 24 ± 5 24 ± 4 .59
Range 19–37 19–38
CD4+ T-cell count at first
HIV-positive visit,
cells/μL, mean (95%CI)
530 (459–601) 593 (537–650) .09
HIV load during follow-
up,a log10 copies/mL,
median (95% CI)




Died during follow-up, no. 2 1 .31
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; HIV,
human immunodeficiency virus; SD, standard deviation.
a Defined as study visits after receipt of a diagnosis of HIV infection.
Figure 1. Results obtained using the BED capture enzyme immunoassay (CEIA; top panels) and the Bio-Rad avidity assay (bottom panels) for women in
the tenofovir (TFV) study arm (A and C) and those in the placebo study arm (B and D). Results for the BED CEIA are reported as normalized optical density units
(OD-n); results for the Bio-Rad avidity assay are reported as avidity indexes (AIs; see “Methods” section). Abbreviation: HIV, human immunodeficiency virus.
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the follow-up period was also similar in the 2 study arms (3 of
35 in the TFV arm vs 4 of 60 in the placebo arm [P = .71]; Fig-
ure 1A and 1B, respectively). The proportion of women in the 2
arms who had an assay-positive result for the Bio-Rad avidity
assay throughout the follow-up period was also similar in the
2 study arms (4 of 35 in the TFV arm vs 3 of 60 in the placebo
arm [P = .42]; Figure 1C and 1D, respectively).
Kaplan–Meier analyses were performed to compare the pro-
portion of women with assay-positive test results as a function
of time after HIV seroconversion (Figure 2). For the BED CEIA
(Figure 2A), there was no significant difference in the results ob-
tained for women in the TFV and placebo arms (P = .58). In
contrast, women in the TFV arm had positive results for the
Bio-Rad avidity assay for a longer time after seroconversion
than women in the placebo arm (P = .036; Figure 2B). The
mean delay in achieving an AI of 80% in the TFV arm, com-
pared with the placebo arm, was 22 days.
In a univariate Cox proportional hazard model, the time to
obtaining an AI result of >80% was significantly longer in the
TFV arm than that the placebo arm (hazard ratio [HR], 0.62;
95% confidence interval [CI], .39–.97; P = .035). In a multivar-
iate model, the association between study arm and antibody
maturation was independent of CD4+ T-cell count and set
point HIV load at the time of HIV seroconversion (HR, 0.52;
95% CI, .32–.84; P = .008).
Antibody titer and antibody avidity were also assessed using
the Luminex assay. There was no significant difference in anti-
body titer for any of the 4 Luminex target antigens for women
in the TFV arm versus those in the placebo arm (Supplementary
Figure 1). However, after seroconversion, there was significantly
lower rate of increase in antibody avidity to the gp120 target an-
tigen (P = .028) and a trend of a lower rate of increase in anti-
body avidity to the gp160 target antigen (P = .056), using linear
mixed effects models (Supplementary Figure 2). These differ-
ences were not observed for either of the 2 gp41 target antigens
(P = .759 for gp41 intact; P = .224 for gp41 truncated).
DISCUSSION
We observed a delay in antibody maturation following HIV in-
fection in women who were using topical TFV gel for PrEP.
This association was observed using 2 independent methods
for assessing antibody avidity (the Bio-Rad avidity assay,
which includes gp160 and p24 target antigens, and the Luminex
assay, for the gp120 target antigen). In contrast, there was no
significant difference in antibody maturation using an assay
that measures the proportion of IgG that is HIV-specific
(BED CEIA) or using the Luminex assay to measure antibody
titer (for any of the 4 target antigens). The association of de-
layed evolution of antibody avidity and TFV gel use was inde-
pendent of HIV load and CD4+ T-cell count measured at the
time of HIV seroconversion. The lack of association with HIV
load indicates that differences in antibody maturation are not
related to viral suppression by TFV; in this setting, viral sup-
pression would have been transient, since study drug was
stopped as soon as HIV infection was detected or diagnosed.
The delayed or absent increases in antibody avidity in women
using TFV gel appear to be selective; these differences were ob-
served for antibodies that bind the Bio-Rad avidity assay target
antigens (gp160 and p24) and for some but not all of the Lumi-
nex antigens (for gp120, but not for gp41 or gp160).
We compared our findings to results from a study of oral
TFV PrEP in rhesus macaques [6]. In both studies, TFV PrEP
was associated with delayed/diminished antibody avidity, with
no impact on antibody titer. In the macaque model, altered evo-
lution of antibody avidity was observed for antibodies directed
Figure 2. Kaplan–Meier analysis showing the proportion of women
crossing the assay cutoff, by time after human immunodeficiency virus
(HIV) seroconversion. A, Time to reach a BED capture enzyme immunoassay
result of 0.8 normalized optical density units (OD-n). B, Time to reach a Bio-
Rad avidity index (AI) of 80%. Results for the TFV arm are shown with a
dashed line; results from the placebo arm are shown with a solid line and
dark shading. Abbreviations: CI, confidence interval; TFV, tenofovir.
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toward gp41; this was not observed in our study. Also, in the
macaque study, peak simian immunodeficiency virus load and
viral load set point were >1 log lower in animals that received
oral TFV PrEP [6]. In contrast, women in the TFV arm, who
received topical gel PrEP in the CAPRISA 004 study, did not
have lower HIV loads than women in the placebo arm at the
time of HIV seroconversion [9]. It is notable that the viral
load set point was higher among women in the TFV arm, com-
pared with those in the placebo arm [12]. Levels of neutralizing
antibodies were reduced following infection in macaques that
received oral TFV PrEP [6]; we did not analyze neutralizing
antibodies in this study. Species differences and other factors
may be responsible for differences observed in antibody matu-
ration and viral load responses in our study and the macaque
study.
ART administered during the acute phase of infection has
also been associated with a diminished antibody avidity and
titer to HIV [13].When ART is discontinued and these individ-
uals no longer had a suppressed viral load, their antibody
responses quickly to rose to levels similar to those of individuals
who did not receive ART during acute infection [5]. Addition-
ally, ART-induced viral suppression in individuals with chronic
HIV infection is associated with a reduction in antibody titer,
and viral breakthrough during ART in these individuals is asso-
ciated with an increase in antibody titer [14–16]. In contrast, an-
tibody avidity does not typically decline during ART-induced
viral load suppression [15, 17, 18].
This report indicates that topical TFV PrEP use influences
the maturation of antibody avidity in individuals who become
infected with HIV. This decreased antibody avidity maturation
may affect population-level incidence estimates calculated using
cross-sectional methods that solely rely on antibody avidity to
differentiate recent from nonrecent infection. The slower avidity
maturation would increase the window period for the assay,
which, if unaccounted for, would result in overestimation of
the population-level incidence. Use of a combination of sero-
logic assays that measure both antibody titer and avidity should
rectify this problem. Further research is needed to identify the
mechanisms involved and to determine whether similar associ-
ations are seen in individuals receiving oral TFV PrEP (rather
than TFV gel). Further research is also needed to determine
whether TFV PrEP use is associated with alternations in viral
diversity/diversification following infection, which could influ-
ence antibody maturation; an initial report did not find altered
diversity in this setting [19]. Finally, it is not known whether the
size or composition of the latently infected viral reservoir is al-
tered in individuals who are infected while taking PrEP. Given
the increase in PrEP use following Food and Drug Administra-
tion approval of oral TFV PrEP, it is important to understand
how PrEP use influences the immune response to HIV infec-
tion. Alterations in antibody maturation may influence the per-
formance of assays used for HIV diagnosis, as well as assays
(such as the Bio-Rad avidity assay) that are used for cross-
sectional estimation of the incidence of HIV infection. These
issues should be considered in surveillance and other studies
when TFV is used for HIV prevention.
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